User menu

Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer.

Bibliographic reference Stefanou, Dimitra T ; Bamias, Aristotelis ; Episkopou, Charikleia ; Kyrtopoulos, Soterios A ; Likka, Maria ; et. al. Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer.. In: PLoS One, Vol. 10, no. 2, p. e0117654 [1-19] (2015)
Permanent URL
  1. R Siegel, CA Cancer J Clin, 64, 9 (2014)
  2. Jayson Gordon C, Kohn Elise C, Kitchener Henry C, Ledermann Jonathan A, Ovarian cancer, 10.1016/s0140-6736(13)62146-7
  3. Kim Ayako, Ueda Yutaka, Naka Tetsuji, Enomoto Takayuki, Therapeutic strategies in epithelial ovarian cancer, 10.1186/1756-9966-31-14
  4. Holschneider Christine H., Berek Jonathan S., Ovarian cancer: Epidemiology, biology, and prognostic factors, 10.1002/1098-2388(200007/08)19:1<3::aid-ssu2>;2-s
  5. RF Ozols, Semin Oncol, 27, 47 (2000)
  6. Z Kemp, Int J Womens Health, 5, 45 (2013)
  7. Fichtinger-Schepman Anne Marie J., Van der Veer Johannis L., Den Hartog Jeroen H. J., Lohman Paul H. M., Reedijk Jan, Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation, 10.1021/bi00324a025
  8. Kartalou Maria, Essigmann John M, Mechanisms of resistance to cisplatin, 10.1016/s0027-5107(01)00141-5
  9. Bowden Nikola A., Nucleotide excision repair: Why is it not used to predict response to platinum-based chemotherapy?, 10.1016/j.canlet.2014.01.005
  10. Deans Andrew J., West Stephen C., DNA interstrand crosslink repair and cancer, 10.1038/nrc3088
  11. Thompson Larry H., Hinz John M., Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: Mechanistic insights, 10.1016/j.mrfmmm.2009.02.003
  12. Dronkert Mies L.G, Kanaar Roland, Repair of DNA interstrand cross-links, 10.1016/s0921-8777(01)00092-1
  13. Mogi Seiki, Oh Dennis H., γ-H2AX formation in response to interstrand crosslinks requires XPF in human cells, 10.1016/j.dnarep.2006.03.009
  14. LJ Kuo, In Vivo, 22, 305 (2008)
  15. Lagerwerf Saskia, Vrouwe Mischa G., Overmeer René M., Fousteri Maria I., Mullenders Leon H.F., DNA damage response and transcription, 10.1016/j.dnarep.2011.04.024
  16. Karst Alison M., Drapkin Ronny, Ovarian Cancer Pathogenesis: A Model in Evolution, 10.1155/2010/932371
  17. Olaussen Ken A., Dunant Ariane, Fouret Pierre, Brambilla Elisabeth, André Fabrice, Haddad Vincent, Taranchon Estelle, Filipits Martin, Pirker Robert, Popper Helmut H., Stahel Rolf, Sabatier Laure, Pignon Jean-Pierre, Tursz Thomas, Le Chevalier Thierry, Soria Jean-Charles, DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy, 10.1056/nejmoa060570
  18. Reed Eddie, ERCC1 Measurements in Clinical Oncology, 10.1056/nejme068162
  19. Weberpals Johanne, Garbuio Kyla, O'Brien Anna, Clark-Knowles Katherine, Doucette Steve, Antoniouk Olga, Goss Glenwood, Dimitroulakos Jim, The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer, 10.1002/ijc.23987
  20. VL Souliotis, Clin Cancer Res, 9, 4465 (2003)
  21. Dimopoulos Meletios A., Souliotis Vassilis L., Anagnostopoulos Athanasios, Papadimitriou Christos, Sfikakis Petros P., Extent of Damage and Repair in thep53Tumor-Suppressor Gene After Treatment of Myeloma Patients With High-Dose Melphalan and Autologous Blood Stem-Cell Transplantation Is Individualized and May Predict Clinical Outcome, 10.1200/jco.2005.07.385
  22. Dimopoulos M. A., Souliotis V. L., Anagnostopoulos A., Bamia C., Pouli A., Baltadakis I., Terpos E., Kyrtopoulos S. A., Sfikakis P. P., Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma, 10.3324/haematol.11435
  23. Stefanou Dimitra T., Episkopou Hara, Kyrtopoulos Soterios A., Bamias Aristotelis, Gkotzamanidou Maria, Bamia Christina, Liakou Christina, Bekyrou Margarita, Sfikakis Petros P., Dimopoulos Meletios-Athanasios, Souliotis Vassilis L., Development and validation of a PCR-based assay for the selection of patients more likely to benefit from therapeutic treatment with alkylating drugs : A PCR-based assay for patient selection in cancer chemotherapy, 10.1111/j.1365-2125.2012.04274.x
  24. Gkotzamanidou M, Sfikakis P P, Kyrtopoulos S A, Bamia C, Dimopoulos M A, Souliotis V L, Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma, 10.1038/bjc.2014.410
  25. Therasse Patrick, Arbuck Susan G., Eisenhauer Elizabeth A., Wanders Jantien, Kaplan Richard S., Rubinstein Larry, Verweij Jaap, Van Glabbeke Martine, van Oosterom Allan T., Christian Michaele C., Gwyther Steve G., New Guidelines to Evaluate the Response to Treatment in Solid Tumors, 10.1093/jnci/92.3.205
  26. K Hamaguchi, Cancer Res, 53, 5225 (1993)
  27. Frgala T., Kalous O., Proffitt R. T., Reynolds C. P., A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations, 10.1158/1535-7163.mct-04-0331
  28. Forchhammer Lykke, Ersson Clara, Loft Steffen, Möller Lennart, Godschalk Roger W. L., van Schooten Frederik J., Jones George D. D., Higgins Jennifer A., Cooke Marcus, Mistry Vilas, Karbaschi Mahsa, Collins Andrew R., Azqueta Amaya, Phillips David H., Sozeri Osman, Routledge Michael N., Nelson-Smith Kirsty, Riso Patrizia, Porrini Marisa, Matullo Giuseppe, Allione Alessandra, Stępnik Maciej, Komorowska Magdalena, Teixeira João Paulo, Costa Solange, Corcuera Laura-Ana, López de Cerain Adela, Laffon Blanca, Valdiglesias Vanessa, Møller Peter, Inter-laboratory variation in DNA damage using a standard comet assay protocol, 10.1093/mutage/ges032
  29. Stellas D., Karameris A., Patsavoudi E., Monoclonal Antibody 4C5 Immunostains Human Melanomas and Inhibits Melanoma Cell Invasion and Metastasis, 10.1158/1078-0432.ccr-06-1585
  30. Moller Peter, The Alkaline Comet Assay: Towards Validation in Biomonitoring of DNA Damaging Exposures, 10.1111/j.1742-7843.2006.pto_167.x
  31. de Feraudy S., Revet I., Bezrookove V., Feeney L., Cleaver J. E., A minority of foci or pan-nuclear apoptotic staining of  H2AX in the S phase after UV damage contain DNA double-strand breaks, 10.1073/pnas.1002175107
  32. Scarpato R., Castagna S., Aliotta R., Azzara A., Ghetti F., Filomeni E., Giovannini C., Pirillo C., Testi S., Lombardi S., Tomei A., Kinetics of nuclear phosphorylation ( -H2AX) in human lymphocytes treated in vitro with UVB, bleomycin and mitomycin C, 10.1093/mutage/get024
  33. Clingen P.H., Wu J.Y.-H., Miller J., Mistry N., Chin F., Wynne P., Prise K.M., Hartley J.A., Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy, 10.1016/j.bcp.2008.03.025
  34. Tompkins Joshua D, Wu Xiling, Her Chengtao, MutS homologue hMSH5: role in cisplatin-induced DNA damage response, 10.1186/1476-4598-11-10
  35. Al-Minawi A. Z., Lee Y.-F., Hakansson D., Johansson F., Lundin C., Saleh-Gohari N., Schultz N., Jenssen D., Bryant H. E., Meuth M., Hinz J. M., Helleday T., The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links, 10.1093/nar/gkp705
  36. Olive Peggy L, Banáth Judit P, The comet assay: a method to measure DNA damage in individual cells, 10.1038/nprot.2006.5
  37. Unger Florian T, Klasen Hermann A, Tchartchian Garri, de Wilde Rudy L, Witte Irene, DNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells, 10.1186/1471-2407-9-359
  38. Alberg Anthony J., Jorgensen Timothy J., Ruczinski Ingo, Wheless Lee, Shugart Yin Yao, Berthier-Schaad Yvette, Kessing Bailey, Hoffman-Bolton Judith, Helzlsouer Kathy J., Kao W.H.Linda, Francis Lesley, Alani Rhoda M., Smith Michael W., Strickland Paul T., DNA repair gene variants in relation to overall cancer risk: a population-based study, 10.1093/carcin/bgs304
  39. Udumudi Anuradha, Jaiswal Malini, Rajeswari N, Desai Neena, Jain S, Balakrishna N, Rao K.Visweswara, Ahuja Y.R, Risk assessment in cervical dysplasia patients by single cell gel electrophoresis assay: a study of DNA damage and repair, 10.1016/s1383-5718(97)00164-2
  40. Lieber Michael R., The Mechanism of Double-Strand DNA Break Repair by the Nonhomologous DNA End-Joining Pathway, 10.1146/annurev.biochem.052308.093131
  41. Hefferin Melissa L., Tomkinson Alan E., Mechanism of DNA double-strand break repair by non-homologous end joining, 10.1016/j.dnarep.2004.12.005
  42. Weterings Eric, Chen David J, The endless tale of non-homologous end-joining, 10.1038/cr.2008.3
  43. Gospodinov Anastas, Herceg Zdenko, Chromatin structure in double strand break repair, 10.1016/j.dnarep.2013.07.006
  44. Povirk Lawrence F., Biochemical mechanisms of chromosomal translocations resulting from DNA double-strand breaks, 10.1016/j.dnarep.2006.05.016
  45. HELLEDAY T, LO J, VANGENT D, ENGELWARD B, DNA double-strand break repair: From mechanistic understanding to cancer treatment, 10.1016/j.dnarep.2007.02.006
  46. Solier S., Sordet O., Kohn K. W., Pommier Y., Death Receptor-Induced Activation of the Chk2- and Histone H2AX-Associated DNA Damage Response Pathways, 10.1128/mcb.00581-08
  47. Huang Ruby YunJu, Chen Geng Bo, Matsumura Noriomi, Lai Hung-Cheng, Mori Seiichi, Li Jingjing, Wong Meng Kang, Konishi Ikuo, Thiery Jean-Paul, Goh Liang, Histotype-specific copy-number alterations in ovarian cancer, 10.1186/1755-8794-5-47
  48. N Colombo, Ann Oncol, 23, vii20 (2013)
  49. Domcke Silvia, Sinha Rileen, Levine Douglas A., Sander Chris, Schultz Nikolaus, Evaluating cell lines as tumour models by comparison of genomic profiles, 10.1038/ncomms3126
  50. Widschwendter Martin, Apostolidou Sophia, Raum Elke, Rothenbacher Dietrich, Fiegl Heidi, Menon Usha, Stegmaier Christa, Jacobs Ian J., Brenner Hermann, Epigenotyping in Peripheral Blood Cell DNA and Breast Cancer Risk: A Proof of Principle Study, 10.1371/journal.pone.0002656
  51. Rotunno M., Hu N., Su H., Wang C., Goldstein A. M., Bergen A. W., Consonni D., Pesatori A. C., Bertazzi P. A., Wacholder S., Shih J., Caporaso N. E., Taylor P. R., Landi M. T., A Gene Expression Signature from Peripheral Whole Blood for Stage I Lung Adenocarcinoma, 10.1158/1940-6207.capr-10-0170
  52. Zander T., Hofmann A., Staratschek-Jox A., Classen S., Debey-Pascher S., Maisel D., Ansen S., Hahn M., Beyer M., Thomas R. K., Gathof B., Mauch C., Delank K.-S., Engel-Riedel W., Wichmann H.- E., Stoelben E., Schultze J. L., Wolf J., Blood-Based Gene Expression Signatures in Non-Small Cell Lung Cancer, 10.1158/1078-0432.ccr-10-0533
  53. Teschendorff Andrew E., Menon Usha, Gentry-Maharaj Aleksandra, Ramus Susan J., Gayther Simon A., Apostolidou Sophia, Jones Allison, Lechner Matthias, Beck Stephan, Jacobs Ian J., Widschwendter Martin, An Epigenetic Signature in Peripheral Blood Predicts Active Ovarian Cancer, 10.1371/journal.pone.0008274
  54. Marsit Carmen J., Koestler Devin C., Christensen Brock C., Karagas Margaret R., Houseman E. Andres, Kelsey Karl T., DNA Methylation Array Analysis Identifies Profiles of Blood-Derived DNA Methylation Associated With Bladder Cancer, 10.1200/jco.2010.31.3577
  55. KW Marshall, Int J Cancer, 126, 1177 (2010)
  56. Anderson D., Najafzadeh M., Gopalan R., Ghaderi N., Scally A. J., Britland S. T., Jacobs B. K., Reynolds P. D., Davies J., Wright A. L., Al-Ghazal S., Sharpe D., Denyer M. C., Sensitivity and specificity of the empirical lymphocyte genome sensitivity (LGS) assay: implications for improving cancer diagnostics, 10.1096/fj.14-254748
  57. Hoebers Frank J.P., Pluim Dick, Verheij Marcel, Balm Alfons J.M., Bartelink Harry, Schellens Jan H.M., Begg Adrian C., Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT), 10.1002/ijc.21919
  58. Reed E., Ozols R. F., Tarone R., Yuspa S. H., Poirier M. C., Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy., 10.1073/pnas.84.14.5024
  59. Wang Li-E, Yin Ming, Dong Qiong, Stewart David J., Merriman Kelly W., Amos Christopher I., Spitz Margaret R., Wei Qingyi, DNA Repair Capacity in Peripheral Lymphocytes Predicts Survival of Patients With Non–Small-Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy, 10.1200/jco.2010.34.3616
  60. Liu Joyce F., Kindelberger David, Doyle Courtney, Lowe Alarice, Barry William T., Matulonis Ursula A., Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients, 10.1016/j.ygyno.2013.08.006
  61. JH Kim, Int J Nanomedicine, 8, 2247 (2013)